Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• GianniniEGFarinatiFCiccareseFPrognosis of untreated hepatocellular carcinomaHepatology201561118419025234419
   PubMed Web of Science ®Google Scholar
• HanPLiHJiangXDual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cellsMol Oncol201711332033428164434
   PubMed Web of Science ®Google Scholar
• Rota CaremoliELabiancaRTivantinib: critical review with a focus on hepatocellular carcinomaExpert Opin Investig Drugs2014231115631574
   PubMed Web of Science ®Google Scholar
• ZhaiBSunXYMechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinomaWorld J Hepatol20135734535223898367
   PubMedGoogle Scholar
• TorrecillaSLlovetJMNew molecular therapies for hepatocellular carcinomaClin Res Hepatol Gastroenterol201539Suppl 1S80S8526206572
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ZhangXJZhangTYYuFFRisk of treatment-related mortality with sorafenib in patients with cancerAsian Pac J Cancer Prev201414116681668624377588
   PubMedGoogle Scholar
• SonpavdeGJeYSchutzFVenous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trialsCrit Rev Oncol Hematol2013871808923317774
   PubMed Web of Science ®Google Scholar
• QiWXMinDLShenZRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisInt J Cancer2013132122967297423225494
   PubMed Web of Science ®Google Scholar
• WesolowskiRAbdel-RasoulMLustbergMPaskellMShapiroCLMacraeERTreatment-related mortality with everolimus in cancer patientsOncologist201419666166824794158
   PubMed Web of Science ®Google Scholar
• GuBGaoWChuHAdverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: a meta-analysisMedicine (Baltimore)20169548e375227902583
   PubMed Web of Science ®Google Scholar
• ZhangDYeJXuTXiongBTreatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysisJ Chemother201325317017523783142
   PubMed Web of Science ®Google Scholar
• ChoueiriTKJeYSonpavdeGIncidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitorsAnn Oncol20132482092209723658373
   PubMed Web of Science ®Google Scholar
• SivendranSLiuZPortasLJJrTreatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysisCancer Treat Rev201238791992522651902
   PubMed Web of Science ®Google Scholar
• MoherDCookDJEastwoodSOlkinIRennieDStroupDFImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analysesLancet199935491931896190010584742
   PubMed Web of Science ®Google Scholar
• SweetingMJSuttonAJLambertPCWhat to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse dataStat Med20042391351137515116347
   PubMed Web of Science ®Google Scholar
• ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
   PubMed Web of Science ®Google Scholar
• MoherDPhamBJonesADoes quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet199835291286096139746022
   PubMed Web of Science ®Google Scholar
• CainapCQinSHuangWTLinifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trialJ Clin Oncol201533217217925488963
   PubMed Web of Science ®Google Scholar
• ChengALKangYKLinDYSunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trialJ Clin Oncol201331324067407524081937
   PubMed Web of Science ®Google Scholar
• JohnsonPJQinSParkJWBrivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyJ Clin Oncol201331283517352423980084
   PubMed Web of Science ®Google Scholar
• KangYKYauTParkJWRandomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinomaAnn Oncol201526122457246326386123
   PubMed Web of Science ®Google Scholar
• KudoMImanakaKChidaNPhase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEur J Cancer201147142117212721664811
   PubMed Web of Science ®Google Scholar
• KudoMHanGFinnRSBrivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trialHepatology20146051697170724996197
   PubMed Web of Science ®Google Scholar
• LlovetJMDecaensTRaoulJLBrivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJ Clin Oncol201331283509351623980090
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKJohnsonPKnoxJJDoxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trialJAMA2010304192154216021081728
   PubMed Web of Science ®Google Scholar
• ZhuAXKudoMAssenatEEffect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trialJAMA20143121576725058218
   PubMed Web of Science ®Google Scholar
• BruixJQinSMerlePRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201738910064566627932229
   PubMed Web of Science ®Google Scholar
• BruixJTakayamaTMazzaferroVAdjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet Oncol201516131344135426361969
   PubMed Web of Science ®Google Scholar
• ZhuAXParkJORyooBYRamucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialLancet Oncol201516785987026095784
   PubMed Web of Science ®Google Scholar
• DuffyAWilkersonJGretenTFHemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapiesHepatology20135731068107723112096
   PubMed Web of Science ®Google Scholar